3/28/2013

Pharmaceutical companies are awaiting a decision from India's Supreme Court, due April 1, that could determine the state of intellectual property protection for branded drugs in India. The case involves whether an amended form of Novartis' cancer treatment Glivec, used to treat chronic myeloid leukemia, is entitled to patent protection against generic competitors. "Big Pharma is nervous because nothing has gone in their favour in the recent past," said pharmaceutical consultant Ajay Kumar Sharma.

Related Summaries